A new dosing protocol reduces dexmedetomidine-associated hypotension in critically ill surgical patients☆,☆☆,★
Introduction
After publication of Too Err is Human: Building a Safer Health System in 1999 by the Institute of Medicine, medication safety has become a top priority in health care [1]. That report focused on the observation that many medical errors involve medications and concluded that health care providers need to design safer systems [2], [3]. Because of complexities of critical illness, patients in the intensive care unit (ICU) are considered to be at increased risk of medication errors and adverse drug events, particularly with intravenous medications [2], [3], [4], [5]. Proposed strategies to improve medication safety in the ICU include intensivist-lead, multidisciplinary rounds with pharmacist participation; standardized drug preparation and administration; computerized prescriber order entry; bar coding technology; computerized intravenous infusion devices; education; and developing a culture of safety [2], [6]. Because most medication errors and many adverse drug events are considered preventable, development of surveillance systems targeting strategies for improvement should help decrease adverse drug events in both the outpatient and the inpatient setting, including the ICU [6].
An essential part of ICU care is to protect patients from themselves during agitation, and this often requires use of sedatives such as propofol or benzodiazepines [7]. In addition, opioids are used to treat pain, a common contributor to agitation in surgical patients. Unfortunately, use of these medications is associated with adverse drug events such as respiratory depression, resulting in increased duration of mechanical ventilation, and development of ventilator-associated pneumonia, all of which increase ICU length of stay [8].
Dexmedetomidine is a sedative with a unique mechanism of action that became available in the United States in 1999 for sedation of critically ill patients [9]. Desirable properties of dexmedetomidine include induction of sedation and analgesia via stimulation of α2-receptors without concomitant respiratory depression by γ-aminobutric acid-mimetic properties that accompany use of many other sedatives [9]. Additional advantages of dexmedetomidine include a relatively short half-life and hepatic metabolism [9]. Described adverse drug reactions with dexmedetomidine include altered blood pressure, nausea, and bradycardia [10], [11]. Hypotension, which is the most commonly reported adverse effect, results from a sympatholytic effect mediated by activation of central α2a-receptors causing vasodilation [9], [12]. Thus, dexmedetomidine has the desirable characteristic of inducing sedation without causing respiratory depression, but it also has potential side effects that might preclude its use during critical illness.
Despite an initial enthusiasm for dexmedetomidine to treat agitation in our surgical ICU, data from our drug surveillance monitoring system suggested an unacceptable incidence of hypotension and bradycardia associated with its use. Closer evaluation revealed that hypotension often occurred when dexmedetomidine dosage was titrated rapidly (more frequently than every 20 minutes) compared with slower rates of titration [13]. Based upon these data, a dosing protocol for dexmedetomidine was developed that allows titration no more frequently than every 30 minutes. In this report, we described reduced occurrence of hypotension associated with dexmedetomidine in our surgical ICU after institution of this dosing protocol.
Section snippets
Materials and methods
Dexmedetomidine was added to the Formulary of Accepted Medications at The Ohio State University Medical Center in 2001 and was restricted to use in the surgical ICU. We previously reported a medication use evaluation performance improvement project of patients receiving dexmedetomidine in the surgical ICU between October 2001 and December 2004 [13]. These data suggested that hypotension occurred more frequently when dexmedetomidine is rapidly titrated. Based on these data, a dosing protocol was
Results
Forty-four patients were included in analysis, including 25 patients that received dexmedetomidine after protocol institution and 19 historic controls that received rapidly titrated dexmedetomidine. Both groups had comparable demographics and admitting services (Table 1, Table 2). Median {25%-75% interquartile range} APACHE II scores upon admission were similar between groups (21 {15-25} protocol group vs 22 {15-29} historic control; P = .38). The mean duration of mechanical ventilation
Discussion
This study suggests that occurrence of hypotension associated with dexmedetomidine use in postoperative ICU patients can be significantly reduced by implementation of a dosing protocol. Although hypotension is a potential adverse effect of any sedative agent [15], [16], [17], [18], [19], [20], [21], [22], our initial experience with dexmedetomidine showed a somewhat higher incidence of hypotension ( approximately 69%) than reported by others (Table 4) [16], [17], [23]. Some have suggested that
Conclusions
Dexmedetomidine is a sedative agent with several unique properties that make it attractive for use in critically ill patients. Although our initial experience demonstrated an unacceptably high incidence of hypotension, use of a dosing protocol was associated with significant reduction in hypotension incidence. Further prospective studies will be required to validate this protocol for use during critical illness and to determine the influence of preadministration volume status upon
References (28)
- et al.
Medication safety and transfusion errors in the ICU and beyond
Crit Care Clin
(2005) - et al.
Building safety into ICU care
J Crit Care
(2002) - et al.
Principles and practices of medication errors in the ICU
Crit Care Clin
(2006) - et al.
The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation
Chest
(1998) - et al.
Dexmedetomidine for sedation and perioperative management of critically ill patients
Semin Anesth Periop Med Pain
(2006) - et al.
ICU sedation after coronary artery bypass surgery: dexmedetomidine-based versus propofol-based sedation regimens
J Cardiothor Vasc Anesth
(2003) - et al.
Pharmacokinetics of dexmedetomidine infusion for sedation of postoperative patients requiring intensive care
Br J Anesth
(2002) - et al.
Medication administration errors in adult patient in the intensive care unit
Intensive Care Med
(2001) - et al.
Preventable adverse drug events in hospitalized patients: a comparison of intensive care and general care units
Crit Care Med
(1997)
Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult
Crit Care Med
Dexmedetomidine: an updated review
Ann Pharmacother
Dexmedetomidine. Drugs
Cited by (62)
Comparison of dexmedetomidine versus propofol on hemodynamics in surgical critically ill patients
2018, Journal of Surgical ResearchPerinatal and neonatal use of sedation and analgesia
2017, Seminars in Fetal and Neonatal MedicineCitation Excerpt :Of concern, the incidence and degree of hypotension after bolus dosing appears to be similar to fentanyl and midazolam. However, avoidance of bolus doses or rapid titration of dexmedetomidine attenuates this adverse effect in adults [49]. No studies have reported the long-term developmental outcome of preterm infants treated with dexmedetomidine.
Comparison of the effects of propofol and emulsified isoflurane alone or combined with dexmedetomidine on induction of anesthesia in dogs
2016, Veterinary Anaesthesia and AnalgesiaCitation Excerpt :It is also reported to decrease central sympathetic outflow and to modify intraoperative cardiovascular responses to noxious stimuli during laparoscopy (Maze & Tranquilli 1991; Aho et al. 1992). Minimal respiratory depression has been reported (Gerlach et al. 2009). In one study of vascular surgery in humans, use of dexmedetomidine weakened the stress response and release of norepinephrine by modulating sympathetic activity (Talke et al. 2000).
Minimizing Motion Artifacts in Intravital Microscopy Using the Sedative Effect of Dexmedetomidine
2022, Microscopy and MicroanalysisEfficacy of dexmedetomidine for foraminal endoscopic surgery
2024, Chinese Journal of Primary Medicine and PharmacyPerioperative Hypotension in Patients Undergoing Orthopedic Upper Extremity Surgery with Dexmedetomidine Sedation: A Retrospective Study
2023, Journal of Personalized Medicine
- ☆
Joseph F. Dasta is a consultant and member of the Hospira Speakers Bureau for dexmedetomidine. None of the other authors have anything to disclose.
- ☆☆
No outside finances were used to fund this study.
- ★
Author contributions—trial design: AG, SS, LM, CC; data collection: AG; data analysis: AG, SS, LM, CC.